Merck的实验卵巢癌药物 获得FDA突破状态 由于有希望的早期结果。 Merck's experimental ovarian cancer drug gets FDA breakthrough status due to promising early results.

Merck收到了FDA的“突破疗法”鉴定,根据早期数据表明抗扰动效果很强,安全情况良好,对针对高级或经常性卵巢癌的实验性药物进行了实验性治疗。 Merck has received FDA Breakthrough Therapy Designation for an experimental drug targeting advanced or recurrent ovarian cancer, based on early data showing strong anti-tumor effects and a good safety profile. 指定旨在加快开发和审查,提供更频繁的FDA互动和加速批准的可能性. The designation aims to speed up development and review, offering more frequent FDA interactions and potential for accelerated approval. 药物通过堵塞癌症发作中的特定途径而起作用。 The drug works by blocking specific pathways involved in cancer progression. Merck计划通过后期试验推进治疗,设法解决未满足的妇科肿瘤学需求。 Merck plans to advance the therapy through later-stage trials, seeking to address unmet needs in gynecologic oncology.